tiprankstipranks
Intellia Therapeutics initiated with an Outperform at Bernstein
The Fly

Intellia Therapeutics initiated with an Outperform at Bernstein

Bernstein initiated coverage of Intellia Therapeutics with an Outperform rating and $54 price target. The firm calls Intellia its top pick in gene editing. Intellia has a strong lead over the field with its in vivo gene editing platform, which is already clinically validated in the liver in ATTR amyloidosis and hereditary angioedema, the analyst tells investors in a research note. The firm believes NTLA-2001’s superior biomarker reduction will translate into superior clinical outcomes versus silencers.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on NTLA:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles